Apoptotic signaling in multiple myeloma: therapeutic implications
- PMID: 12953804
- DOI: 10.1007/BF02983378
Apoptotic signaling in multiple myeloma: therapeutic implications
Abstract
Fifteen thousand new cases of multiple myeloma (MM) will occur in the United States in 2003, and the disease remains incurable. Diverse classes of chemotherapeutic agents induce cell death or apoptosis in MM cells; however, prolonged drug exposures ultimately induce chemoresistance. The mechanisms whereby MM cells resist drugs include alterations in intracellular signaling as well as adherence and cytokines in the bone marrow (BM) microenvironment. Novel agents that target the MM cell in its BM microenvironment are needed to both enhance anti-MM activity and prevent development of drug resistance. Delineation of cellular growth and apoptotic signaling pathways in MM cells may identify molecules that serve as novel therapeutic targets on the basis of interruption of MM cell growth or triggering of MM cell death.
Similar articles
-
Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications.Apoptosis. 2003 Aug;8(4):337-43. doi: 10.1023/a:1024164700094. Apoptosis. 2003. PMID: 12815276 Review.
-
Apoptosis in multiple myeloma: therapeutic implications.Apoptosis. 2001 Feb-Apr;6(1-2):47-55. doi: 10.1023/a:1009620027205. Apoptosis. 2001. PMID: 11321040 Review.
-
Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways.Clin Lymphoma Myeloma Leuk. 2018 May;18(5):311-320. doi: 10.1016/j.clml.2018.03.007. Epub 2018 Mar 17. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29606369 Review.
-
Novel anti-myeloma agents and angiogenesis.Leuk Lymphoma. 2008 Apr;49(4):677-89. doi: 10.1080/10428190701861686. Leuk Lymphoma. 2008. PMID: 18398734 Review.
-
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.Cancer Res. 2005 Sep 15;65(18):8350-8. doi: 10.1158/0008-5472.CAN-05-0163. Cancer Res. 2005. PMID: 16166312
Cited by
-
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.Blood. 2005 Jun 1;105(11):4470-6. doi: 10.1182/blood-2004-09-3794. Epub 2005 Feb 10. Blood. 2005. PMID: 15705788 Free PMC article.
-
Apoptosis of multiple myeloma.Int J Hematol. 2004 Oct;80(3):224-31. doi: 10.1532/ijh97.04107. Int J Hematol. 2004. PMID: 15540896 Free PMC article. Review.
-
The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.Blood Cancer J. 2014 Jun 13;4(6):e219. doi: 10.1038/bcj.2014.38. Blood Cancer J. 2014. PMID: 24927408 Free PMC article.
-
Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma.Adv Hematol. 2012;2012:842945. doi: 10.1155/2012/842945. Epub 2012 Aug 2. Adv Hematol. 2012. PMID: 22919394 Free PMC article.
-
Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials.Oncotarget. 2018 May 4;9(34):23704-23717. doi: 10.18632/oncotarget.25281. eCollection 2018 May 4. Oncotarget. 2018. PMID: 29805768 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical